XUANZHUBIO-B(02575),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

02575 XUANZHUBIO-B

Not Yet Opened 05-14 16:09:12

18.900

-0.980

-4.93%

High20.800	Low18.200	Vol1.13M
Open20.800	D1 Closing19.880	Amplitude13.08%
Mkt Cap9.79B	Tradable Cap9.79B	Total Shares518.00M
T/O21.31M	T/O Rate0.22%	Tradable Shares517.95M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"02575","market":"HK","secType":"STK","nameCN":"XUANZHUBIO-B","latestPrice":18.9,"timestamp":1778746152177,"preClose":19.88,"halted":0,"volume":1134000,"delay":0,"changeRate":-0.04929577464788735,"floatShares":517947790,"shares":518000000,"eps":-0.6117016393699432,"marketStatus":"Not Yet Opened","change":-0.98,"latestTime":"05-14 16:09:12","open":20.8,"high":20.8,"low":18.2,"amount":21309255,"amplitude":0.130785,"askPrice":18.91,"askSize":3000,"bidPrice":18.8,"bidSize":1000,"shortable":0,"etf":0,"ttmEps":-0.6059308691872077,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1778808600000},"marketStatusCode":0,"adr":0,"listingDate":1760457600000,"exchange":"SEHK","adjPreClose":19.88,"openAndCloseTimeList":[[1778722200000,1778731200000],[1778734800000,1778745600000]],"volumeRatio":0.4906111136935145,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02575/wiki","defaultTab":"wiki","newsList":[{"id":"1175245965","title":"Xuanzhu Biopharma Converts 357.25 Million Unlisted Shares into H Shares, Lifting Issued Share Base by 68.97%","url":"https://stock-news.laohu8.com/highlight/detail?id=1175245965","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1175245965?lang=en_us&edition=fundamental","pubTime":"2026-05-12 19:02","pubTimestamp":1778583763,"startTime":"0","endTime":"0","summary":"Xuanzhu Biopharmaceutical Co., Ltd. (Xuanzhu Biopharma) has completed the conversion of 357.25 million unlisted shares into the same number of H shares, according to its Next Day Disclosure Return...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112216216","title":"Xuanzhu Biopharmaceutical Completes H-Share Full Circulation, Converts 357.25 Million Unlisted Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=1112216216","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1112216216?lang=en_us&edition=fundamental","pubTime":"2026-05-12 17:03","pubTimestamp":1778576591,"startTime":"0","endTime":"0","summary":"Xuanzhu Biopharmaceutical Co., Ltd. announced on 12 May 2026 that it has finalised its H-share full-circulation programme, converting 357.25 million unlisted domestic shares into H shares. The newly...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126727555","title":"XUANZHUBIO-B Completes Full Circulation of H Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=1126727555","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1126727555?lang=en_us&edition=fundamental","pubTime":"2026-05-12 16:34","pubTimestamp":1778574869,"startTime":"0","endTime":"0","summary":"XUANZHUBIO-B (02575) has announced that on May 12, 2026, a total of 357 million non-tradable shares have been converted. These converted H shares will commence trading on the Stock Exchange starting at 9:00 a.m. on May 13, 2026.","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634296712","title":"Xuanzhu Biopharmaceutical converts 357,245,794 unlisted shares into H shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2634296712","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634296712?lang=en_us&edition=fundamental","pubTime":"2026-05-12 16:31","pubTimestamp":1778574709,"startTime":"0","endTime":"0","summary":"Xuanzhu Biopharmaceutical completed conversion of 357,245,794 unlisted shares into H shares on May 12.Converted H shares start trading in Hong Kong at 9:00 a.m. on May 13.H-share count rises to 517,947,790 from 160,701,996; unlisted shares drop to zero.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xuanzhu Biopharmaceutical Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on May 12, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nNDL6srlSn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","02575","BK1593","00460","BK1191","BK1600"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633972317","title":"Here's Why We're Not Too Worried About Xuanzhu Biopharmaceutical's (HKG:2575) Cash Burn Situation","url":"https://stock-news.laohu8.com/highlight/detail?id=2633972317","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633972317?lang=en_us&edition=fundamental","pubTime":"2026-05-06 07:15","pubTimestamp":1778022949,"startTime":"0","endTime":"0","summary":"Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2575/xuanzhu-biopharmaceutical-shares/news/heres-why-were-not-too-worried-about-xuanzhu-biopharmaceutic","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2575/xuanzhu-biopharmaceutical-shares/news/heres-why-were-not-too-worried-about-xuanzhu-biopharmaceutic","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["02575","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196960560","title":"XUANZHUBIO-B Accelerates Domestic Commercialization and Secures Major Overseas Licensing Deal, Broadening Growth Prospects","url":"https://stock-news.laohu8.com/highlight/detail?id=1196960560","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1196960560?lang=en_us&edition=fundamental","pubTime":"2026-04-28 08:27","pubTimestamp":1777336035,"startTime":"0","endTime":"0","summary":"Revenue surged by over 70% year-on-year, signaling imminent commercialization breakthroughs for its three key drivers... In 2025, XUANZHUBIO-B successfully entered a phase of full-scale...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157313573","title":"Xuanzhu Biopharm initiates full electronic delivery of shareholder communications; urges investors to submit email contacts","url":"https://stock-news.laohu8.com/highlight/detail?id=1157313573","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1157313573?lang=en_us&edition=fundamental","pubTime":"2026-04-27 20:03","pubTimestamp":1777291390,"startTime":"0","endTime":"0","summary":"On 28 April 2026, Xuanzhu Biopharmaceutical Co., Ltd. (“Xuanzhu Biopharm”) issued a reminder to its registered shareholders confirming the transition to electronic dissemination of all corporate...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161574939","title":"玄珠生物-B(02575)2025年营收同比增长72%至0.52亿元 多款肿瘤创新药完成商业化布局","url":"https://stock-news.laohu8.com/highlight/detail?id=1161574939","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1161574939?lang=en_us&edition=fundamental","pubTime":"2026-04-27 19:47","pubTimestamp":1777290440,"startTime":"0","endTime":"0","summary":"玄珠生物-B（02575）公布截至2025年12月31日止年度业绩，年内实现营收约0.52亿元（较上年同期的0.30亿元增长72.0%），主要来自产品销售规模扩大与商业化推进。公司期内经营效率提升，全年净亏损较上年同期大幅收窄55.9%至约2.46亿元，显示收入增长与费用优化带来的运营杠杆效应。...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"玄珠生物-B(02575)2025年营收同比增长72%至0.52亿元 多款肿瘤创新药完成商业化布局","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144640823","title":"Xuanzhu Biopharmaceutical publishes inaugural 2025 ESG report; R&D spend reaches RMB 183.84 million and Scope 1-2 emissions total 1,237 tCO₂e","url":"https://stock-news.laohu8.com/highlight/detail?id=1144640823","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1144640823?lang=en_us&edition=fundamental","pubTime":"2026-04-27 19:43","pubTimestamp":1777290200,"startTime":"0","endTime":"0","summary":"Xuanzhu Biopharmaceutical Co., Ltd. released its first Environmental, Social and Governance (ESG) report covering the 2025 fiscal year. The document outlines governance enhancements, climate-related...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168267258","title":"Hong Kong Market Midday Update: Hang Seng Index Drops 1.12% in Morning Session, Coal Stocks Buck the Trend","url":"https://stock-news.laohu8.com/highlight/detail?id=1168267258","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1168267258?lang=en_us&edition=fundamental","pubTime":"2026-04-23 12:12","pubTimestamp":1776917553,"startTime":"0","endTime":"0","summary":"The Hang Seng Index declined by 1.12%, shedding 292 points to reach 25,870. The Hang Seng Tech Index fell by 2.31%. Morning session turnover reached HK$142.6 billion. LOPAL TECH (02465) surged over...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"6e25ff80ead11b7a981a82ced5db5608","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GWLLY","513600","03330","XPEV","BK4585","HSTECH","02883","YZCAY","600115","HHImain","600988","002490","02589","603906","600029","06693","00670","HTImain","BK1587","09868","01055","02333","600188","BK1110","BK1233","BK4588","02833","03668","601633","601808","HSI","HSImain","MCHmain","02635","02575","BK1616","00568","06181","01171","01797","02465"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174006676","title":"Xuanzhu Bio-B Shares Surge Over 8% on NG-350A Phase 1b FORTRESS Study Preliminary Results Presentation at 2026 AACR","url":"https://stock-news.laohu8.com/highlight/detail?id=1174006676","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1174006676?lang=en_us&edition=fundamental","pubTime":"2026-04-23 11:10","pubTimestamp":1776913837,"startTime":"0","endTime":"0","summary":"Xuanzhu Bio-B (02575) saw its shares rise more than 8% during the trading session. As of the time of writing, the stock had climbed 8.65% to HK$28.4, with a turnover of HK$119 million. On April 20,...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575","BK1191","BK4588","VXUS","BK4017","BK4585","NG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141536607","title":"SIHUAN PHARM Shares Climb Nearly 3% as Subsidiary XUANZHUBIO-B Presents Promising Data on Diraoc in First-Line NSCLC Treatment at AACR","url":"https://stock-news.laohu8.com/highlight/detail?id=1141536607","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1141536607?lang=en_us&edition=fundamental","pubTime":"2026-04-21 11:40","pubTimestamp":1776742822,"startTime":"0","endTime":"0","summary":"SIHUAN PHARM (00460) rose nearly 3%, with the stock up 2.29% to HK$1.34 at the time of writing. Turnover reached HK$18.04 million. The increase follows an announcement on April 20 that the group's...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","00460","BK4588","VXUS","BK1515","BK1593","BK4585","BK1600","02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113433094","title":"CATL Shareholder Sets A-Share Transfer Price at 410.34 Yuan; Nitrogen Fertilizer Prices May Climb Further","url":"https://stock-news.laohu8.com/highlight/detail?id=1113433094","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1113433094?lang=en_us&edition=fundamental","pubTime":"2026-04-21 07:40","pubTimestamp":1776728442,"startTime":"0","endTime":"0","summary":"Global nitrogen fertilizer exporter Fertiglobe indicated that nitrogen fertilizer prices have surged to nearly double pre-Iran conflict levels and could rise further as key supplies remain blocked in...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0165289439.USD","LU0650527681.SGD","LU2125910849.SGD","LU0261950470.USD","LU0149534421.HKD","LU0672654166.SGD","LU1997245177.USD","LU2357125470.USD","03393","LU0051755006.USD","SG9999001903.USD","SG9999000459.SGD","HK0000165453.HKD","LU0405327494.USD","LU0823437842.USD","BK1515","HK0000181112.HKD","IE00BPRC5H50.USD","LU2152927971.USD","LU0048575426.USD","03200","BK1129","LU0254981946.USD","LU2778985437.USD","LU0516422440.USD","LU0531971595.HKD","00941","300750","LU0164865239.USD","000756","00719","LU0326950275.SGD","LU2449936058.SGD","LU0823414551.USD","LU2506952410.USD","LU0124384867.USD","LU0516422952.EUR","LU1961090484.USD","LU3063872942.SGD","SG9999003461.SGD","LU1226287792.SGD","LU0231483743.USD","LU0210526637.USD","LU1951186391.HKD","LU2097828557.USD","LU2242644610.SGD","01093","LU0821914370.USD","IE0008368742.USD","BK1147","LU1064131003.USD","SG9999001846.SGD","LU0828238088.HKD","IE00B29SXG58.USD","LU1880383440.USD","LU0505663152.USD","LU1978683503.SGD","IE00B8HQ1Z84.USD","LU0572944931.SGD","02607","LU1880383366.USD","LU0543330483.HKD","LU2041044095.USD","LU0501845795.SGD","LU2360107325.USD","LU2289578879.USD","LU0516422366.SGD","LU2153592121.USD","LU0469268626.HKD","LU1861214812.USD","LU1861219969.SGD","02476","LU0871576103.HKD","BK1154","LU0192582467.USD","LU0979878070.USD","META","LU1242518931.SGD","LU2476274308.USD","LU0048388663.USD","LU0594300179.USD","LU1251922891.USD","LU1226287875.USD","LU2045819591.USD","LU0235996351.USD","IE00B031HY20.USD","LU1934453819.USD","00451","LU0143863784.USD","LU2506951792.HKD","LU0106259558.USD","LU2399975544.HKD","LU0214875030.USD","LU0594300419.USD","BK4141","LU1719994722.HKD","LU0449509016.USD","LU1328277881.USD","601607","LU1807302812.USD","300476","LU2125910500.SGD","LU2097828631.EUR","LU2328871848.SGD","SNFRY","LU2506952337.HKD","LU0054450605.USD","SG9999014674.SGD","BK1594","SG9999002463.SGD","603093","02575","LU0048580855.USD","LU0269904917.USD","LU0405327148.USD","LU2148510915.USD","LU1146622755.USD","LU1769817096.USD","LU2039709279.SGD","LU1102505929.USD","LU0011963245.USD","LU0107464264.USD","BK1116","BK0224","LU0164872284.USD","LU0315179316.USD","LU1008478684.HKD","SGXZ49509284.SGD","LU1979443071.USD","LU0072913022.USD","LU0611395673.USD","LU0359201612.USD","LU2294711713.HKD","LU1781817850.SGD","BK4519","LU2097828805.USD","SG9999001689.USD","LU0828237940.HKD","LU0326948709.USD","PLUG","06608","COIN","LU1051768304.USD","LU0607220059.USD","IE00BZ08YT58.USD","LU0312595415.SGD","LU1655091616.SGD","IE00B5MMRT66.SGD","LU0359202008.SGD","LU1023057109.AUD","LU1770034418.SGD","LU1226288253.USD","IE00BZ08YS42.EUR","LU0651947912.USD","LU2298064838.USD","LU0880133367.SGD","LU0516423174.USD","00297","LU2249611893.SGD","SHPMY","IE00BZ08YR35.GBP","IE00B8L5B284.USD","IE00BZ199S13.USD","LU2348773727.SGD","LU0132412106.USD","LU2394011477.USD","IE0003795394.USD","LU2580892789.USD","301200","IE00B3M56506.USD","LU0302445910.USD","LU0823414478.USD","LU2097828714.EUR","LU2360108059.USD","LU0455707207.USD","LU0651946864.USD","LU1721428347.USD","LU2424517915.HKD","600941","LU0314109678.HKD","LU2476274720.SGD","LU1993786604.SGD","HK0000181138.USD","LU0449515922.USD","SG9999004220.SGD","LU1868837565.USD","LU1102505762.USD","BK4588","LU0251143458.SGD","LU1820825898.SGD","LU2275660780.HKD","IE0008369823.USD","LU1868838027.USD","LU2092937221.SGD","LU1242518857.USD","LU1969619763.USD","LU0509642566.USD","LU2238339852.HKD","LU1303224171.USD","04335","IE0032431581.USD","LU0502904849.HKD","LU0531970944.HKD","LU0823426480.USD","LU2298321311.HKD","SG9999002828.SGD","LU0605514214.HKD","02691","LU0049853897.USD","LU1939255532.USD","LU0359201885.HKD","LU1997244956.HKD","LU0456827905.SGD","LU1048588211.SGD","LU2477742899.HKD","IE00B543WZ88.USD","LU2495084118.USD","LU0188438112.USD","LU1051769294.HKD","INTC","BK4585","LU1813983027.USD","IE0003851619.USD","BK4526","LU2097828474.EUR","LU0327786744.USD","LU2294711473.HKD","LU1152091754.HKD","SGXZ81163826.USD","BK1554","TSLA","LU0067412154.USD","LU2580892862.HKD","LU0259732245.USD","03750","LU0828237510.HKD","LU1188198961.HKD","09696","BK1610","002466","LU2506952253.HKD","LU0823426308.USD","LU2153591404.USD","LU0043850808.USD","IE00BD6J9T35.USD","LU0106959298.USD","LU0370786039.SGD","LU0029875118.USD","LU0128522157.USD","LU0143863198.USD","LU1769817179.HKD","LU1997245094.SGD","03983","LU0593848301.USD","LU0047713382.USD","LU1960683339.HKD","LU0516423091.SGD","LU1808992512.USD","LU0463099449.HKD","LU0724618433.USD","LU0181495838.USD","LU0228659784.USD","LU1255011170.USD","LU1720050803.USD","LU0039217434.USD","LU0106252389.USD","LU1226288170.HKD","LU1515016050.SGD","CBLUY","01866","LU2348774022.SGD","LU1064130708.USD","LU0072462343.USD","BK1191","LU0140636845.USD","LU1152091168.USD","LU2298322129.HKD","LU0328353924.USD","EVS.SI","LU0320764755.SGD","LU1039395188.USD","LU1794554557.SGD","LU1831875114.USD","SG9999000327.SGD","BK1521","LU1226287529.USD","LU1580142542.USD","LU1048596156.SGD","LU0348805143.USD","LU0244354667.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156604450","title":"Xuanzhu Biopharm: NG-350A Delivers 50% Composite Response in Early Phase 1b Rectal Cancer Trial at AACR 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=1156604450","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1156604450?lang=en_us&edition=fundamental","pubTime":"2026-04-20 17:03","pubTimestamp":1776675811,"startTime":"0","endTime":"0","summary":"Xuanzhu Biopharmaceutical Co., Ltd. (Xuanzhu Biopharm) reported preliminary data from the ongoing Phase 1b FORTRESS study evaluating NG-350A combined with chemoradiotherapy (CRT) in patients with...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628574340","title":"Xuanzhu says Phase 1b NG-350A plus chemoradiotherapy hits 50% composite response rate","url":"https://stock-news.laohu8.com/highlight/detail?id=2628574340","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628574340?lang=en_us&edition=fundamental","pubTime":"2026-04-20 16:51","pubTimestamp":1776675091,"startTime":"0","endTime":"0","summary":"Xuanzhu Biopharmaceutical announced preliminary Phase 1b FORTRESS data for NG-350A were presented at 2026 AACR on April 20, 2026.Early results indicated NG-350A combined with chemoradiotherapy improved response outcomes in mismatch repair-proficient locally advanced rectal cancer versus expectations for chemoradiotherapy alone.Safety profile appeared supportive, with no serious adverse events or new safety signals attributed to NG-350A in initial patients completing active treatment.Program supports Xuanzhu strategy to advance NG-350A development in Greater China under an exclusive license from Akamis.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xuanzhu Biopharmaceutical Co. Ltd. published the original content used to generate this ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260420:nNDL95R4QQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00460","BK1191","BK1515","BK1600","BK1593","02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126932556","title":"XUANZHUBIO-B to Present Phase III Data for Diraok in First-Line ALK-Positive Advanced NSCLC at 2026 AACR","url":"https://stock-news.laohu8.com/highlight/detail?id=1126932556","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1126932556?lang=en_us&edition=fundamental","pubTime":"2026-04-19 18:20","pubTimestamp":1776594034,"startTime":"0","endTime":"0","summary":"XUANZHUBIO-B (02575) announced that the Group presented results from the Phase III DIAMOND-2 clinical study of Diraok as a first-line treatment for anaplastic lymphoma kinase (ALK) positive advanced...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4134","ALK","BK4008","02575","III","BK4588","BK4500","BK4585","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628076134","title":"Xuanzhu says Phase III trial shows dirozalkib cuts lung cancer progression risk 53%","url":"https://stock-news.laohu8.com/highlight/detail?id=2628076134","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628076134?lang=en_us&edition=fundamental","pubTime":"2026-04-19 18:07","pubTimestamp":1776593223,"startTime":"0","endTime":"0","summary":"Xuanzhu Biopharmaceutical presented Phase III DIAMOND-2 trial results for ALK-positive advanced non-small cell lung cancer at 2026 AACR, held April 17-22, 2026.Dirozalkib outperformed crizotinib in first-line treatment, extending time without disease worsening in a 275-patient China study.Study also showed stronger tumor shrinkage durability, including improved control of brain lesions versus comparator.Safety profile supported continued use, with mostly mild-to-moderate gastrointestinal side effects.Dirozalkib received China NMPA clearance in August 2025 for ALK-positive locally advanced or metastatic NSCLC in patients not previously treated with an ALK inhibitor.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xuanzhu Biopharmaceutica","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260419:nNDL4PxWxZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1593","02575","00460","BK1515","BK1600","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124608444","title":"Xuanzhu Biopharmaceutical gains HKEX green light for full circulation of 357.25 million H shares","url":"https://stock-news.laohu8.com/highlight/detail?id=1124608444","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1124608444?lang=en_us&edition=fundamental","pubTime":"2026-04-17 17:05","pubTimestamp":1776416700,"startTime":"0","endTime":"0","summary":"Hong Kong – Xuanzhu Biopharmaceutical Co., Ltd. announced that the Hong Kong Stock Exchange has approved the listing and dealing of 357.25 million H shares converted from unlisted shares under its...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189853321","title":"XUANZHUBIO-B Receives Green Light from Hong Kong Stock Exchange for H-Share Full Circulation Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=1189853321","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1189853321?lang=en_us&edition=fundamental","pubTime":"2026-04-17 16:34","pubTimestamp":1776414856,"startTime":"0","endTime":"0","summary":"XUANZHUBIO-B (02575) announced that on April 16, 2026, the Hong Kong Stock Exchange approved the listing and trading of 357 million H-shares. These shares will be converted from non-traded shares as...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628134279","title":"Xuanzhu Biopharma wins HKEX approval to list 357,245,794 converted H shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2628134279","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628134279?lang=en_us&edition=fundamental","pubTime":"2026-04-17 16:31","pubTimestamp":1776414695,"startTime":"0","endTime":"0","summary":"Hong Kong stock exchange cleared Xuanzhu Biopharmaceutical to list 357,245,794 H shares converted from unlisted shares under its H-share full circulation plan.Transaction would lift total listed H shares to 517,947,790 from 160,701,996 once conversion and trading procedures are completed.Xuanzhu flagged additional updates as it moves toward completion of conversion and listing.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xuanzhu Biopharmaceutical Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on April 17, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260417:nNDL24Xh0W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","BK1515","02575","00460","BK1600","BK1593"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.xuanzhubio.com","stockEarnings":[{"period":"1week","weight":-0.0644},{"period":"1month","weight":-0.4202},{"period":"3month","weight":-0.7009},{"period":"6month","weight":-0.7045},{"period":"1year","weight":0.6293},{"period":"ytd","weight":-0.7319}],"compareEarnings":[{"period":"1week","weight":-0.0089},{"period":"1month","weight":0.02},{"period":"3month","weight":-0.0067},{"period":"6month","weight":-0.0069},{"period":"1year","weight":0.1163},{"period":"ytd","weight":0.0296}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Xuanzhu Biopharmaceutical Co Ltd is a China-based company principally engaged in biopharmaceutical business. The Company is primarily engaged in business of research and development, manufacturing and commercialization of innovative drugs, focusing on a number of therapeutic areas such as digestion, oncology and non-alcoholic steatohepatitis (NASH). The Company’s main products include KBP-3571, XZP-3287 and XZP-3621. The Company mainly conducts its businesses in the domestic market.","exchange":"SEHK","name":"XUANZHUBIO-B","nameEN":"XUANZHUBIO-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"XUANZHUBIO-B(02575),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest XUANZHUBIO-B(02575) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"XUANZHUBIO-B,02575,XUANZHUBIO-B股票,XUANZHUBIO-B股票老虎,XUANZHUBIO-B股票老虎国际,XUANZHUBIO-B行情,XUANZHUBIO-B股票行情,XUANZHUBIO-B股价,XUANZHUBIO-B股市,XUANZHUBIO-B股票价格,XUANZHUBIO-B股票交易,XUANZHUBIO-B股票购买,XUANZHUBIO-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"XUANZHUBIO-B(02575),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest XUANZHUBIO-B(02575) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}